Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 10

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 10
---
- 10 - Q4 2024 Results Biopharma | Innovation Achieved All 2024 Milestones and Set for Continued Success 1 The MAA follows a Decentralized Procedure (DCP) with the Reference Member State Germany (PEI) and the Concerned Member States Au stria (AGES) and Spain (AEMPS); 2 FDA BLA submission on Jan 9, 2025 Introductory Remarks Business Performance Financials Final remarks Annex Fibrinogen Key Portfolio Addition Alpha - 1 AT 15% SC Phase 1/2 Cohort 2 Tx 1: First patient enrolled H1 PRECIOSA Last Patient Out – LPLV H1 OSIG in DED – Start of GLP Preclinical studies H1 Yimmugo BLA FDA approval H1 Xembify ® bi - weekly dosing FDA approval H2 GIGA2339 in HBV Phase 1 IND submission H2 PRECIOSA topline results H2 Gamunex in bags conformance lots production H2 Fibrinogen Congenital & Acquired Deficiency MAA 1 /BLA submission 2 H2 Fibrinogen AdFirst clinical study completed Regulatory (EU and US) approvals submitted - EU 1 st country approval ( Q3‘25) - US approval (Q4’25) BLA accepted, PDUFA 27 Dec 2025 Market Launch - First in the EU, later the US On track to share study results, engage HCPs - Manuscript submitted for publication - Abstract submitted for presentation at ISICEM in March (Brussels), planning for US congress 1 2 3 4

- 11 - Q4 2024 Results Rahul Srinivasan Chief Financial Officer (CFO) A Strong Finish to a Record Year

- 12 - Q4 2024 Results Q4 2024 FY 2024 Introductory Remarks Business Performance Financials Final remarks Annex Var vs. PY Reported Var vs. PY Reported (in million EUR except %) +10.3% cc 7,212 +13.6% cc 1,976 REVENUE +12.5% 2,795 +10.8% 766 GROSS PROFIT +100bps 38.7% - 30bps 38.8% Margin +21.7% 1,779 +18.6% 526 EBITDA ADJ. +250bps 24.